We would like to invite you to Olink virtual event at 13:30 CET on 24th March, at Erasmus MC Rotterdam, “Protein biomarkers in cardiovascular disease: from the discovery to clinical implementation.”
Cardiovascular disease is the leading cause of death globally. It is crucial to identify at-risk individuals early on, deliver more precise and targeted therapy, reduce risk of recurrent CVD events. In this seminar you will learn how protein biomarkers help to better understand pathophysiology of heart failure and atrial fibrillation, predict disease progression or recurrence of CVD events. We will discuss future and perspectives of implementation of protein biomarkers into clinical practice to optimize decision-making and therapeutic management.
“Serial proteomics in heart failure for prognostication and subphenotyping”
Vicente Artola Arita MD
UMC Groningen
“Omics in atrial fibrillation"
“Targeted proteomics improves cardiovascular risk prediction”
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.